Noah Stansfield

The observational BASECAMP-1 screening study has started to identify patients with advanced solid tumors harboring somatic human leukocyte antigen-A*02 loss of heterozygosity who would be eligible to receive the novel Tmod CAR T-cell therapy, A2B530, if their cancer relapses after standard of care treatment.

Ben Creelan, MD, discusses several of the methods evaluating cellular therapies currently in the works across the non–small cell lung cancer field.